RSR. S. Scott

R. S. Scott

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


R. S. Scott has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Plasma Levels of Sex Hormone-binding Globulin, Corticosteroid-binding Globulin and Cortisol in Overweight Subjects who Develop Impaired Fasting Glucose: A 3-Year Prospective Study

    by J. G. Lewis, B. I. Shand, C. M. Frampton, P. A. Elder, R. S. Scott

    Circulating sex hormone-binding globulin (SHBG), corticosteroid-binding globulin (CBG), and total and calculated free cortisol were measured in 206 overweight subjects to investigate whether or not they were markers of insulin resistance. Measurements were carried out on two occasions 36 months apart and subjects were grouped according to fasting plasma glucose. Fifty-one subjects, with a normal basal fasting glucose (<5.6 mmol/l) developed impaired fasting glucose 3 years later (≥5.6 mmol/l). Analysis either in toto or based on gender showed a highly significant increase in fasting insulin and insulin resistance, a modest increase in body mass index (BMI), but importantly no change in plasma SHBG, CBG, or cortisol concentrations. Subjects (n=101) with a normal fasting glucose both at baseline (<5.6 mmol/l) and at 36 months showed no significant change in fasting insulin, insulin resistance, SHBG, CBG, cortisol, or BMI. Cross-sectional analysis of the study population showed that plasma SHBG correlated negatively with insulin resistance both in men and women. Overall SHBG at baseline was not predictive of changes in fasting glucose. In females, plasma CBG correlated negatively with BMI. The major finding is that overweight subjects who developed impaired fasting glucose showed no significant change in plasma SHBG, CBG or cortisol, and therefore these indices are probably not early markers of insulin resistance in overweight subjects.

  • Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure

    by C H Strey, J M Young, J H Lainchbury, C M Frampton, M G Nicholls, A M Richards, R S Scott

    Objectives: To investigate the effect of short-term statin treatment on impaired endothelium-dependent vasodilatation and haemodynamic abnormalities typically occurring in chronic heart failure (CHF). Methods: In a double-blind, crossover study endothelium-dependent vasodilatation was measured in conduit and resistance vessels of 23 patients with non-ischaemic CHF after 6 weeks of placebo and 40 mg atorvastatin. The haemodynamic impact was assessed by cardioendocrine hormones, echocardiography and clinical indicators of CHF. Results: Cholesterol concentrations were population average (low density lipoprotein 3.56 (SEM 0.16) mmol/l, triglycerides 1.70 (0.20) mmol/l and high density lipoprotein 1.17 (0.07) mmol/l). In resistance vessels, the area under the curve ratio during acetylcholine infusion increased from 9.2 (1.9) with placebo to 12.2 (2.1) with statin (p < 0.01). This improvement was reversed during co-infusion with the nitric oxide antagonist N G-monomethyl-l-arginine. In conduit arteries, flow-mediated dilatation increased from 5.64 (SEM 0.88)% with placebo to 6.83 (0.97)% with statin (p < 0.05). Endothelium-independent vasodilatation did not change (p = 0.68 for conduit and p = 0.45 for resistance vessels). Endothelin 1 and atrial natriuretic peptide (ANP) decreased from 1.57 (0.08) and 51.3 (1.0) with placebo to 1.42 (0.09) pg/ml (p < 0.05) and 42.1 (7.5) pmol/l (p < 0.05), respectively, with statin. Conclusions: In patients with non-ischaemic CHF and population-average cholesterol concentrations, short-term statin treatment improves endothelial function in conduit and resistance vessels and lowers plasma endothelin 1 and ANP concentrations.


  • The postprandial state does not impair endothelial function in women with Type 2 diabetes irrespective of glycaemic control

    by C. H. Strey, J. Young, M. Collier, C. M. Florkowski, B. I. Shand, R. S. Scott

    Aims/hypothesis The postprandial state has been shown to be associated with endothelial dysfunction, a predictor of cardiovascular morbidity. In Type 2 diabetes, postprandial metabolic excursions are prolonged and exaggerated, but less pronounced if glycaemic control is optimised. We investigated the impact of improved glycaemic control on endothelial function in the postprandial state. Methods We studied 19 postmenopausal women with Type 2 diabetes and ten non-diabetic subjects. Participants with diabetes were re-studied 3 months after intensive glucose regulation. We measured forearm blood flow by strain gauge plethysmography during rest, during acetylcholine infusion and post ischaemia in the fasting state, and again 3 hours after a mixed meal (660 kcal, 55% fat). Results Endothelium-dependent vasodilation was impaired in the diabetic group (p1c reduction of 0.96% (pp p pp<0.005). There was no difference in fasting and postprandial endothelium-dependent vasodilation before and after improved glucose regulation in either group. Conclusions/interpretation The postprandial state does not impair endothelial function in non-diabetic women and does not make pre-existing endothelial dysfunction worse in women with Type 2 diabetes, irrespective of glycaemic control.


  • Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance

    by B. I. Shand, R. S. Scott, P. A. Elder, P. M. George

    Aim:  Adiponectin is a protein produced exclusively by adipocytes with putative insulin‐sensitizing and anti‐atherogenic properties. This cross‐sectional study investigated the relationship between plasma adiponectin and a range of anthropometric, glycaemic, lipid and inflammatory parameters in overweight and obese subjects expressing characteristics of the metabolic syndrome. Methods:  Subjects were selected for the study from a clinical database, if they were non‐diabetic, overweight [body mass index (BMI) > 25] and had features of the metabolic syndrome. The subjects were grouped according to BMI (25–30, 31–35 and >35 kg/m 2 ) and then stratified for insulin resistance [homeostasis model assessment (HOMA) %S]. One hundred and ninety‐seven patients (109 males and 88 females) were selected for the study by taking an equal number with the highest and lowest HOMA indices from each of the three BMI groups. Plasma adiponectin concentration was measured in duplicate by radioimmunoassay, and the relationship between these levels and the other parameters was investigated using correlation and multiple linear regression analyses. Results:  Plasma adiponectin concentration was higher in females than males (median 10.3 vs. 7.1 µg/ml, p < 0.001) despite being matched for BMI. In both genders, adiponectin levels were inversely related to BMI, waist circumference, percentage body fat, insulin resistance and the fasting plasma concentration of leptin. A direct correlation in both sexes was found between adiponectin levels and high‐density lipoprotein (HDL)‐cholesterol, apolipoprotein A1 and age. Multiple linear regression analyses showed that the independent determinants of low plasma adiponectin concentrations were gender, age, BMI, insulin resistance and HDL‐cholesterol. An association between reduced adiponectin and increased high‐sensitivity plasma C‐reactive protein concentration was observed only in female subjects and was independent of anthropometric variables. Our observation that adiponectin levels increase with age differs from the majority of other studies and may simply reflect the demographics of the population studied. Conclusions:  This study shows that adiponectin is an important molecular link between obesity, insulin resistance and atherogenic lipoproteins. It is possible that plasma adiponectin concentration may be a convenient marker for identifying subjects with the metabolic syndrome who may progress to impaired glucose tolerance. Longitudinal studies are required in order to verify this clinical application of adiponectin.


    • 1 August 2001
      • Vol. 14  (4) , 201-6

    A comparison of post-prandial changes in flow-mediated dilatation in patients with type 2 diabetes with and without macroalbuminuria.

    by B I Shand, R S Scott, C M Florkowski, H Ikram

    During the post-prandial period there is a decrease in systemic vascular resistance. This study compared meal-induced changes in flow-mediated dilatation (FMD) in patients with Type 2 diabetes with and without evidence of diabetic nephropathy as defined by the presence of macroalbuminuria. The effects on FMD of other factors such as smoking history, antihypertensive treatment and insulin use were also examined. Twelve patients with macroalbuminuria (>300 mg albumin/day) and 12 age- and sex-matched patients with normoalbuminuria (<50 mg albumin/day) participated in the study. Following a 12-hr overnight fast, forearm basal and reactive hyperaemic blood flow was assessed by venous occlusion plethysmography before and 2-hr after ingestion of a meal (2750 kJ) consisting of 56% fat, 26% carbohydrate and 16% protein. Plasma lipid and glycaemic indices were measured at the same times. The combined and grouped data was analysed using paired t tests and correlation and regression analyses. The meal resulted in significant increases in plasma glucose and triglyceride concentrations. While the meal resulted in a similar increase in basal blood flow rate in both patient groups, post-meal reactive hyperaemic flow increased significantly (p=0.04) in normoalbuminuric patients (mean individual increase: 33%) but remained unchanged in patients with macroalbuminuria (mean individual increase: 4%). The use of antihypertensive agents and insulin was also associated with an attenuated post-prandial hyperaemic response. In summary, our study demonstrated that the degree of renal impairment in patients with Type 2 diabetes may influence vasoactivity following a meal. Patients with evidence of diabetic nephropathy had a decreased post-prandial hyperaemic response, a result that indicated a reduced vasodilator reserve. The mechanism of this reduction in vasodilatation of peripheral vessels during the post-prandial period is probably multifactorial. These changes in vasoactivity have the potential to combine with other cardiovascular risk factors to enhance the development of atheroma.


    • 8 June 2001
      • Vol. 114  (1133) , 260-2

    Implementation of evidence based cardiovascular risk treatments by general practitioners.

    by K Crossen, R S Scott, G R McGeoch, P M George

    To review general practitioner (GP) implementation of evidence based cardiovascular risk reducing strategies in subjects with coronary heart disease (CHD). Audit of patient records of randomly selected GPs. There were 326 subjects with CHD under the care of 21 doctors. Except for smoking, details of lifestyle measures were rarely found in the notes. Advice on diet and exercise was mentioned in 51% and 23.3% of records respectively. Aspirin and beta-blockers were widely used. Of patients with drug untreated values of total cholesterol (TC) and/or TC/HDL exceeding National Heart Foundation (NHF) guidelines, 71% were prescribed lipid-modifying drugs. NHF targets for TC (< or = 5.0 mmol/l) were achieved by 37% and for TC/HDL (< or = 4.5) by 60%. TC remained above 5.5 mmol/L in 120 cases. Lipid results from tests within the last 12 months were found in 60% of cases. Recording of lifestyle treatments in subjects with CHD appears to be assigned low priority. Cardioprotective treatments were widely used. Cholesterol levels were recorded frequently and of those with values exceeding NHF guidelines, nearly 3/4 were on medication. Recommended targets for lipid parameters were being achieved by <50% of patients. More frequent monitoring could improve this outcome

  • Lipid peroxidation and hemorheology as risk factors in young survivors of myocardial infarction

    by C.J. Lintott, B.I. Shand, R.S. Scott, L. Pickering, T. Walmsley